{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:29:20Z","timestamp":1789439360386,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) illness poses a significant burden in children yet is understudied in those &amp;gt;2\u00a0years old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified patients aged \u226417\u00a0years hospitalized with RSV between July 2010 and March 2023 using Ontario\u2019s administrative healthcare data. RSV-specific hospitalizations were defined by ICD-10-CA codes (B97.4, J12.1, J20.5, J21.0) and included overnight stays. Key outcomes included hospitalization frequency, intensive care unit (ICU) use, mechanical ventilation, supplemental oxygen, length of stay, mortality, and costs. Risk conditions included chronic respiratory diseases, congenital malformations, and cystic fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 23\u2009930 RSV hospitalizations; annual counts ranged from 1356 (2010-2011) to 4298 (2022-2023). Children &amp;lt;2\u00a0years accounted for 84% of hospitalizations, though risk conditions were more common in those aged 2-17\u00a0years (35% vs. 7%). In 2022-2023, hospitalizations were ~2-fold, ~3-fold, and ~5-fold higher than previous years (2010-2021) for those &amp;lt;12\u00a0months, 12-&amp;lt;24\u00a0months, and 2-17\u00a0years, respectively. Median length of stay was 69\u00a0h. Annual median cost per hospitalization was $5070 (IQR: $4486-6742). ICU admission occurred in 12% of cases, with median costs over twice that of non-ICU stays ($12\u2009042 vs. $5070). ICU use ranged from 7% to 16% in &amp;lt;2\u00a0years and 10%-35% in 2-17\u00a0years. In-hospital mortality was 0.12%, higher among those with risk conditions (&amp;lt;2\u00a0years: 0.61%; 2-17\u00a0years: 1.02%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study highlighted the burden associated with RSV hospitalizations for people aged \u226417\u00a0years and those who may be more impacted by RSV illness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpids\/piaf079","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T13:12:33Z","timestamp":1756559553000},"source":"Crossref","is-referenced-by-count":2,"title":["Hospitalizations Associated With Respiratory Syncytial Virus Illness Among Children and Adolescents in Ontario, Canada"],"prefix":"10.1093","volume":"14","author":[{"given":"Alexandra","family":"Goyette","sequence":"first","affiliation":[{"name":"Access and Value, Pfizer Canada , Kirkland, QC, H9J 2M5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Gabriela","family":"Grajales","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Canada , Kirkland, QC, H9H 2M5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshayne B","family":"Fell","sequence":"additional","affiliation":[{"name":"Global Respiratory Vaccines and Antivirals, Pfizer Inc. , New York City, NY, 1001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Rodopoulou","sequence":"additional","affiliation":[{"name":"Global Database Studies, Real World Evidence, IQVIA , Athens, 152 32 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceryl","family":"Tan","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions, Canada Inc , Mississauga, ON, L4W5P1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Nightingale","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions, Canada Inc , Mississauga, ON, L4W5P1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Esther","family":"Perez Trejo","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions, Canada Inc , Kirkland, QC, H9H 5M3 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum S","family":"Neish","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Solutions, Canada Inc , Mississauga, ON, L4W5P1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazini","family":"Nzula","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Canada , Kirkland, QC, H9H 2M5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2025092810414854300_ref1","doi-asserted-by":"publisher","first-page":"105666","DOI":"10.1016\/j.earlhumdev.2022.105666","article-title":"New strategies for the prevention of respiratory syncytial virus (RSV)","volume":"174","author":"Messina","year":"2022","journal-title":"Early Hum Dev"},{"key":"2025092810414854300_ref2","doi-asserted-by":"publisher","first-page":"e4521302","DOI":"10.1155\/2017\/4521302","article-title":"Burden of respiratory syncytial virus hospitalizations in Canada","volume":"2017","author":"Mitchell","year":"2017","journal-title":"Can Respir J"},{"key":"2025092810414854300_ref3","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"2025092810414854300_ref4","doi-asserted-by":"publisher","first-page":"e0150416","DOI":"10.1371\/journal.pone.0150416","article-title":"Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data","volume":"11","author":"Pisesky","year":"2016","journal-title":"PLoS ONE"},{"key":"2025092810414854300_ref5","doi-asserted-by":"publisher","first-page":"e2416077","DOI":"10.1001\/jamanetworkopen.2024.16077","article-title":"Pediatric respiratory syncytial virus hospitalizations, 2017-2023","volume":"7","author":"Fitzpatrick","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025092810414854300_ref6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40121-017-0167-9","article-title":"Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States","volume":"6","author":"Parikh","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2025092810414854300_ref7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jpids\/piad045","article-title":"Estimating the incidence of first RSV hospitalization in children born in Ontario","volume":"12","author":"Buchan","year":"2023","journal-title":"Canada J Pediatric Infect Dis Soc"},{"key":"2025092810414854300_ref8","doi-asserted-by":"publisher","first-page":"00593","DOI":"10.1183\/23120541.00593-2021","article-title":"Respiratory syncytial virus-associated hospitalisation in children aged \u22645\u00a0years: a scoping review of literature from 2009 to 2021","volume":"8","author":"Noble","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025092810414854300_ref9","doi-asserted-by":"publisher","first-page":"E1140","DOI":"10.1503\/cmaj.210919","article-title":"Potential resurgence of respiratory syncytial virus in Canada","volume":"193","author":"Lavoie","year":"2021","journal-title":"CMAJ"},{"key":"2025092810414854300_ref10","doi-asserted-by":"publisher","first-page":"e0287395","DOI":"10.1371\/journal.pone.0287395","article-title":"Changes in hospitalizations and emergency department respiratory viral diagnosis trends before and during the COVID-19 pandemic in Ontario, Canada","volume":"18","author":"Habbous","year":"2023","journal-title":"PLoS ONE"},{"key":"2025092810414854300_ref11","volume-title":"Respiratory Virus Report, Week 27\u2014Ending July 8, 2023,","year":"2023"},{"key":"2025092810414854300_ref12","volume-title":"Canada, P. H. A. Of. Respiratory Virus Report, Week 27\u2014Ending July 4, 2020,","year":"2020"},{"key":"2025092810414854300_ref13","doi-asserted-by":"publisher","first-page":"E948","DOI":"10.9778\/cmajo.20200219","article-title":"Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study","volume":"9","author":"Thampi","year":"2021","journal-title":"CMAJ Open"},{"key":"2025092810414854300_ref14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(24)01699-4","article-title":"Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children","volume":"404","author":"Pecenka","year":"2024","journal-title":"Lancet"},{"key":"2025092810414854300_ref15","article-title":"Guidelines on person-level costing using administrative databases in Ontario","author":"Wodchis","year":"2013"},{"key":"2025092810414854300_ref16","first-page":"e36342","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","journal-title":"Cureus"},{"key":"2025092810414854300_ref17","doi-asserted-by":"publisher","first-page":"e2147447","DOI":"10.1001\/jamanetworkopen.2021.47447","article-title":"Prevalence, cost, and variation in cost of pediatric hospitalizations in Ontario, Canada","volume":"5","author":"Gill","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025092810414854300_ref18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1503\/cmaj.150064","article-title":"A 3-year study of high-cost users of health care","volume":"188","author":"Wodchis","year":"2016","journal-title":"CMAJ"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf079\/64167244\/piaf079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/9\/piaf079\/64167244\/piaf079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/9\/piaf079\/64167244\/piaf079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T14:41:54Z","timestamp":1759070514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf079\/8244669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf079","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,30]]},"article-number":"piaf079"}}